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Effect of Cardiogenic Shock Hospital Volume on Mortality in Patients
With Cardiogenic Shock
Shahzad Shaeﬁ, MD; Brian O’Gara, MD; Robb D. Kociol, MD; Karen Joynt, MD, MPH; Ariel Mueller, MA; Junaid Nizamuddin, MD;
Eitezaz Mahmood, BS; Daniel Talmor, MD, MPH; Sajid Shahul, MD, MPH
Background-—Cardiogenic shock (CS) is associated with signiﬁcant morbidity, and mortality rates approach 40% to 60%. Treatment
for CS requires an aggressive, sophisticated, complex, goal-oriented, therapeutic regimen focused on early revascularization and
adjunctive supportive therapies, suggesting that hospitals with greater CS volume may provide better care. The association
between CS hospital volume and inpatient mortality for CS is unclear.
Methods and Results-—We used the Nationwide Inpatient Sample to examine 533 179 weighted patient discharges from 2675
hospitals with CS from 2004 to 2011 and divided them into quartiles of mean annual hospital CS case volume. The primary
outcome was in-hospital mortality. Multivariate adjustments were performed to account for severity of illness, relevant
comorbidities, hospital characteristics, and differences in treatment. Compared with the highest volume quartile, the adjusted
odds ratio for inpatient mortality for persons admitted to hospitals in the lowest-volume quartile (≤27 weighted cases per year)
was 1.27 (95% CI 1.15 to 1.40), whereas for admission to hospitals in the low-volume and medium-volume quartiles, the odds
ratios were 1.20 (95% CI 1.08 to 1.32) and 1.12 (95% CI 1.01 to 1.24), respectively. Similarly, improved survival was observed
across quartiles, with an adjusted inpatient mortality incidence of 41.97% (95% CI 40.87 to 43.08) for hospitals with the lowest
volume of CS cases and a drop to 37.01% (95% CI 35.11 to 38.96) for hospitals with the highest volume of CS cases. Analysis of
treatments offered between hospital quartiles revealed that the centers with volumes in the highest quartile demonstrated
signiﬁcantly higher numbers of patients undergoing coronary artery bypass grafting, percutaneous coronary intervention, or intra-
aortic balloon pump counterpulsation. A similar relationship was demonstrated with the use of mechanical circulatory support
(ventricular assist devices and extracorporeal membrane oxygenation), for which there was signiﬁcantly higher use in the higher
volume quartiles.
Conclusions-—We demonstrated an association between lower CS case volume and higher mortality. There is more frequent use of
both standard supportive and revascularization techniques at the higher volume centers. Future directions may include examining
whether early stabilization and transfer improve outcomes of patients with CS who are admitted to lower volume centers. ( J Am
Heart Assoc. 2015;4:e001462 doi: 10.1161/JAHA.114.001462)
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C ardiogenic shock (CS) is a highly morbid, often fatalcondition for which timely advanced therapy is critical.
This syndrome, the hallmark of which is acute myocardial
contractile dysfunction with resultant systemic hypoperfusion,
is most commonly the result of acute myocardial infarction,
decompensated heart failure, postcardiotomy shock, or acute
myocarditis. The mortality associated with CS approaches 40%
to 60%.1–4 The current standard of care in CS management
includes timely aggressive medical management, revasculari-
zation with percutaneous coronary intervention (PCI)5,6 or
coronary artery bypass grafting (CABG),7 and adjunctive use
of mechanical circulatory devices including intra-aortic bal-
loon pump counterpulsation (IABP) and ventricular assist
devices.8–10 A recent database review of the temporal trends
in the management of CS complicating ST-segment elevation
myocardial infarction from 2003 to 2010 revealed an increase
in overall incidence of roughly 55% but with signiﬁcantly
decreased in-hospital mortality, which could be explained by a
concomitant increase in the use of early mechanical revascu-
larization and IABP.11
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Despite the high morbidity and mortality associated with
CS, little is known about why some hospitals may have better
outcomes than others for this condition. A possibility is that
CS case volume may play a role. An expansive body of
literature demonstrates the volume–outcome relationship in a
number of medical conditions, operations, and proce-
dures.6,12–20 Consensus guidelines exist regarding threshold
numbers for institutional competency of both total and
primary PCI, pointing toward worse outcomes below these
recommended thresholds.14,21,22 This relationship has not
been explored for patients with CS.
In this study, we ﬁrst set out to examine whether larger
centers were more likely to use current standard of care
therapies and advanced circulatory support devices. Second,
we sought to determine whether higher annual hospital CS
volume was associated with lower mortality from CS. Finally,
we sought to determine whether the volume–outcome
relationship for CS was independent of other patient,
institutional, and geographic characteristics that are predic-
tive of increased survival.
Methods
Data Source
The Nationwide Inpatient Sample (NIS) was the administrative
database used in this study. The NIS is a nationally represen-
tative database created by the Agency for Healthcare Research
and Quality that provides annual data on 8 million hospital
stays. It contains discharge data from a 20% stratiﬁed sample of
1000USnonfederal specialtyandpublichospitalsandacademic
medical centers that, when weighted, encompasses 97% of all
hospital discharges in the United States.23 The NIS data set
includes data regarding patient demographics and comorbidi-
ties, hospital characteristics, inpatient mortality rates, and
patient disposition, with each hospitalization considered as an
individual entry to the database. Because theNIShasnopatient-
level identiﬁers, the Institutional Review Board at Beth Israel
Deaconess Medical Center granted this study exempt status.
The NIS validates the data by performing annual external
and internal quality assessments. Validations of the NIS data
set have performed well when compared against the Amer-
ican Hospital Association Annual Survey database, the
National Hospital Discharge Survey from the National Center
for Health Statistics, and the Medicare Provider Analysis and
Review (MEDPAR) inpatient data from the Centers for
Medicare and Medicaid Services.24
Study Population
The study population included all patients in the NIS with a
diagnosis of CS from 2004 through 2011. NIS data can be
weighted to produce national-level estimates by using
standard stratum-speciﬁc discharge weights provided by
the Healthcare Cost and Utilization Project. Weighting is
used to produce accurate unbiased estimates. Patients
diagnosed with CS were identiﬁed by the presence of
International Classiﬁcation of Diseases, ninth revision,
clinical modiﬁcation (ICD-9-CM) code 78551 in the list of
diagnoses generated during the course of their hospital
stay. Validation studies based on this deﬁnition have
demonstrated very high speciﬁcity (99.3%), moderate sen-
sitivity (59.8%), and very high positive (78.8%) and negative
(98.1%) predictive value when used to identify the diagnosis
of CS.25
Exposure, Outcome, and Covariates
The exposure of interest was the mean yearly CS case
volume per hospital divided into quartiles. The primary
outcome was inpatient mortality. Those patients who died
in skilled nursing care and intermediate-care facilities or
free-standing hospice care were excluded from the analysis.
Potential confounders such as age, severity of illness, race,
hospital teaching status, hospital region, and mechanical
ventilation were identiﬁed and adjusted for in our ﬁnal
analysis. Comorbid conditions that could potentially inﬂu-
ence patient outcome were identiﬁed using the Elixhauser
Comorbidity Index, which has been shown to possess
excellent discriminative power for predicting in-hospital
mortality when analyzing administrative databases.26 Elix-
hauser comorbidities were developed by the Agency for
Healthcare Research and Quality using ICD-9 coding for
comorbidity identiﬁcation at patient discharge. These com-
orbidities are present on admission but are not directly
related to the main reason for hospitalization. Commonly
performed procedures that could inﬂuence patient outcome
(eg, PCI and CABG for early revascularization) were
identiﬁed using ICD-9-CM procedure codes and adjusted
for in the ﬁnal analysis. Early revascularization was deﬁned
as CABG or PCI within 24 hours of admission. To address
transfer to a high-volume center as a potentially competing
outcome, we excluded patients transferred to any acute-
care facility.
Statistical Analysis
All analyses were performed using SAS 9.3 (SAS Institute)
and SUDAAN 10.0 (Research Triangle Institute) to account
for the complex survey design of the NIS. Frequencies and
percentages were calculated and weighted to reﬂect
national estimates. Weighted estimates were used for the
analyses to produce accurate unbiased estimates. Categor-
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Table 1. Patient Characteristics at Presentation
Annual Hospital Volume of Cardiogenic Shock
Weighted N (%)
P Value≤27 Cases 28 to 58 Cases 59 to 106 Cases ≥107 Cases
No. of hospitals 2046 (76.49) 366 (13.68) 177 (6.62) 86 (3.21)
No. of discharges 133 241 (24.99) 134 464 (25.22) 135 051 (25.33) 130 423 (24.46)
Patient characteristics
Age group, y
<18 5052 (4.05) 6296 (5.19) 6775 (5.64) 10 265 (8.41) <0.001
18 to 44 32 369 (25.96) 38 660 (31.85) 38 311 (31.91) 44 989 (36.87)
45 to 64 63 094 (50.61) 61 139 (50.36) 61 198 (50.97) 57 035 (46.74)
65 to 84 24 062 (19.30) 15 246 (12.56) 13 733 (11.44) 9712 (7.96)
≥85 97 (0.08) 59 (0.05) 58 (0.05) 24 (0.02)
Female sex 59 746 (44.80) 52 187 (40.72) 50 958 (39.87) 50 311 (38.57) <0.001
Race
White 81 962 (75.29) 77 492 (72.48) 80 974 (76.13) 73 755 (68.84) 0.003
Black 10 511 (9.66) 11 606 (10.85) 9776 (9.19) 16 999 (15.87)
Hispanic 9391 (8.63) 10 163 (9.51) 6727 (6.33) 7864 (7.34)
Asian or Pacific Islander 3074 (2.82) 3248 (3.04) 4054 (3.81) 2288 (2.14)
Native American 752 (0.69) 943 (0.88) 440 (0.41) 621 (0.58)
Other 3174 (2.92) 3466 (3.24) 4388 (4.13) 5610 (5.24)
Patient comorbidities
Anterior STEMI 15 990 (11.91) 20 178 (15.65) 19 118 (14.83) 15 318 (11.58) <0.001
Inferior STEMI 14 626 (10.89) 18 480 (14.33) 17 335 (13.44) 11 751 (8.88) <0.001
Other STEMI 16 959 (12.63) 12 827 (9.95) 11 154 (8.65) 7593 (5.74) <0.001
NSTEMI 31 575 (23.51) 28 767 (22.31) 29 876 (23.17) 26 668 (20.16) 0.003
Old MI 8810 (6.61) 9217 (7.19) 8975 (7.02) 10 531 (8.07) 0.06
Coronary artery disease 56 564 (42.12) 66 789 (51.80) 69 449 (53.86) 64 805 (48.99) <0.001
Cardiac arrest 23 339 (17.50) 24 059 (18.77) 22 173 (17.35) 19 768 (15.15) <0.001
Congestive heart failure 44 079 (33.05) 39 711 (29.58) 36 888 (28.86) 31 535 (24.17) <0.001
Pulmonary circulation disease 4945 (3.71) 4430 (3.46) 4698 (3.68) 5085 (3.90) 0.41
Valvular heart disease 12 820 (9.61) 12 164 (9.49) 13 786 (10.79) 9696 (7.43) 0.02
Peripheral vascular disease 10 240 (7.68) 10 919 (8.52) 11 160 (8.73) 11 599 (8.89) 0.001
Hypertension 56 539 (42.40) 54 673 (42.66) 53 656 (41.98) 52 159 (39.98) 0.35
Diabetes without chronic complications 27 085 (20.31) 25 235 (19.69) 25 119 (19.65) 23 803 (18.25) 0.05
Diabetes with chronic complications 6526 (4.89) 5896 (4.60) 5730 (4.48) 4946 (3.79) 0.002
Renal failure 28 985 (21.73) 25 520 (19.91) 26 046 (20.38) 27 068 (20.75) 0.004
Coagulopathy 13 202 (9.90) 16 511 (12.88) 20 130 (15.75) 26 819 (20.56) <0.001
Obesity 6485 (4.86) 6938 (5.41) 7666 (6.00) 7766 (5.95) 0.001
Mitral disease 10 613 (7.96) 13 407 (10.46) 16 740 (13.10) 15 960 (12.23) <0.001
Aortic disease 6340 (4.75) 6498 (5.07) 7395 (5.79) 8731 (6.69) <0.001
Chronic pulmonary disease 30 646 (22.98) 26 517 (20.69) 26 772 (20.94) 20 975 (16.08) <0.001
Paralysis 3068 (2.30) 2885 (2.25) 2715 (2.12) 2839 (2.18) 0.66
MI indicates myocardial infarction; NSTEMI, non–ST-segment elevation myocardial infarction; STEMI, ST-segment elevation myocardial infarction.
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ical variables are presented as frequencies or proportions
and were compared using the chi-square test. Inpatient
mortality differences between hospital quartiles were ana-
lyzed by ﬁtting multivariate logistic regression models
sequentially to calculate odds ratios (ORs) and 95% CIs.
An unadjusted logistic regression model was used to
estimate the OR for inpatient mortality among patients
with CS relative to quartiles of volume for CS. We then
used a multivariate adjusted model, adjusting for patient
age group, sex, Elixhauser Comorbidity Index, race, hospital
location, and early revascularization. To account for in-
hospital clustering, we used generalized estimating
equations with robust variance estimates. All tests were
2-sided, and P values <0.05 were considered statistically
signiﬁcant.
Results
Demographics and Clinical Patient
Characteristics
We identiﬁed 533 179 weighted patient discharges with CS.
Demographics and clinical characteristics are shown in
Tables 1 and 2. Women accounted for 41% of cases, and
the majority of the patients were white (73.2%). The median
yearly CS volume was 58 cases per year. When grouped into
quartiles, the mean yearly CS volume was distributed into
groups of hospitals treating ≤27 cases (n=133 241), 28 to 58
cases (n=134 464), 59 to 106 cases (n=135 051), and ≥107
cases (n=130 423) per year. Hospitals in the higher volume
quartiles treated a signiﬁcantly higher percentage of patients
with coronary artery disease (49.0% versus 42.1%), mitral
valvular disease (12.2% versus 8.0%), aortic valvular disease
(6.7% versus 4.8%), obesity (6.0% versus 4.9%), and coagul-
opathy (20.6% versus 9.9%) compared with the lower volume
centers.
Hospital and Regional Characteristics
Hospitals with the highest CS volumes were more likely to be
urban, large, academic centers (Table 3). Among hospitals
with <59 cases, rural and urban nonteaching hospitals
accounted for the highest proportion of discharges (76.9%
and 52.5% for quartiles 1 and 2, respectively). In contrast,
these hospitals represented only 6.0% of discharges at the
highest volume centers.
Clinical Management and Quality of Care
Patients at the higher volume hospitals were signiﬁcantly
more likely to receive certain treatments both in terms of
supportive therapy in the setting of organ dysfunction (ie,
hemodialysis) and modalities for deﬁnitive revascularization
(Table 2). Patients in the highest volume quartiles were
signiﬁcantly more likely to receive early revascularization
within 24 hours of admission (34.1% versus 17.1%) than
Table 2. Treatment Effects
Annual Hospital Volume of Cardiogenic Shock
Weighted N (%)
P Value≤27 Cases 28 to 58 Cases 59 to 106 Cases ≥107 Cases
Early revascularization (total) 27 664 (20.60) 50 905 (39.48) 53 992 (41.88) 48 143 (36.39) <0.001
Thrombolysis 2034 (1.53) 1783 (1.39) 1982 (1.55) 1416 (1.09) 0.002
Percutaneous coronary intervention 22 343 (16.64) 37 537 (29.11) 35 212 (27.31) 24 931 (18.85) <0.001
Coronary artery bypass graft (total) 6663 (4.96) 16 403 (12.72) 21 882 (16.97) 25 614 (19.36) <0.001
Valvular surgery 1694 (1.26) 5047 (3.91) 8368 (6.49) 12 957 (9.79) <0.001
Intra-aortic balloon pump 22 382 (16.78) 40 587 (31.67) 42 070 (32.91) 35 495 (27.21) <0.001
Ventricular assist device 82 (0.06) 320 (0.25) 1577 (1.23) 4350 (3.33) <0.001
Biventricular assist device 29 (0.02) 19 (0.02) 140 (0.11) 285 (0.22) <0.001
TandemHeart device 49 (0.04) 132 (0.10) 232 (0.18) 644 (0.49) <0.001
Extracorporeal membrane oxygenation 403 (0.30) 324 (0.25) 760 (0.59) 2878 (2.21) <0.001
Mechanical ventilation 71 760 (53.81) 70 556 (55.05) 71 591 (56.01) 69 082 (52.95) 0.14
Hemodialysis 9246 (6.93) 11 358 (8.86) 12 238 (9.57) 14 631 (11.22) <0.001
Treatment effects within 24 hours
Early revascularization within 24 hours 2623 (17.13) 5259 (34.49) 6406 (39.73) 5922 (34.14) <0.001
Valvular surgery within 24 hours 259 (1.69) 693 (4.54) 1079 (6.69) 1685 (9.72) <0.001
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patients in the lowest volume quartile. In terms of
contemporary speciﬁc revascularization options, the 2
centers with volumes in the higher quartile demonstrated
signiﬁcantly higher numbers of patients undergoing CABG
or PCI. A similar relationship was demonstrated with the
use of mechanical circulatory support including IABP,
extracorporeal membrane oxygenation, the TandemHeart
device (CardiacAssist, Inc), ventricular assist devices, and
biventricular assist devices, all of which were used more
often at the higher volume centers. In contrast, the lowest
quartile hospitals used thrombolysis more than the centers
in higher volume quartiles; this therapy confers less of a
mortality beneﬁt than contemporary revascularization strat-
egies.27
Inpatient Mortality
The crude inpatient mortality was 38.9%. Decreased survival
was seen across the strata as mean annual hospital volume
decreased from the highest quartile (>106 weighted cases per
year) to the lowest quartile (<28 weighted cases per year).
Compared with the highest quartile of CS volume (quartile 4),
patients cared for in hospital quartiles 1, 2, and 3 had
increased unadjusted odds of inpatient mortality by 58% (OR
Table 3. Hospital Characteristics
Annual Hospital Volume of Cardiogenic Shock
Weighted N (%)
P Value≤27 Cases 28 to 58 Cases 59 to 106 Cases ≥107 Cases
Transfer into the hospital
Not transferred in 69 887 (90.94) 64 075 (83.28) 62 907 (76.81) 64 223 (64.42) <0.001
Transferred from another acute care hospital 4350 (5.66) 10 118 (13.15) 15 990 (19.52) 32 009 (32.11)
Transferred from another health facility 2611 (3.40) 2750 (3.57) 3000 (3.66) 3456 (3.47)
Transfer out of the hospital
Not a transfer 27 156 (66.35) 31 642 (70.37) 28 252 (71.13) 42 322 (74.40) <0.001
Transferred out to a different acute care hospital 5113 (12.49) 3133 (6.97) 1685 (4.24) 1463 (2.57)
Transferred out to another type of health facility 8660 (21.16) 10 193 (22.67) 9779 (24.62) 13 098 (23.03)
Admission source
Emergency department 53 285 (73.05) 44 109 (61.83) 33 581 (53.59) 17 702 (42.23) <0.001
Another hospital 4102 (5.62) 8389 (11.76) 13 303 (21.23) 11 309 (26.98)
Another health facility 1663 (2.28) 1994 (2.80) 2438 (3.89) 993 (2.37)
Teaching status
Urban nonteaching 76 154 (57.64) 62 556 (49.02) 50 534 (39.96) 7842 (6.04) <0.001
Urban teaching 30 545 (23.12) 60 678 (47.55) 72 436 (57.29) 122 067 (93.96)
Bed size of hospital
Small 29 245 (22.14) 7141 (5.60) 5664 (4.48) 1118 (0.86) <0.001
Medium 47 140 (35.68) 32 333 (25.34) 22 587 (17.86) 3089 (2.38)
Large 55 729 (42.18) 88 136 (69.07) 98 195 (77.66) 125 701 (96.76)
Hospital region
Northeast 24 424 (18.31) 17 974 (14.02) 21 624 (16.92) 30 132 (23.10) 0.02
Midwest 32 356 (24.26) 27 664 (21.58) 31 578 (24.70) 27 133 (20.80)
South 51 182 (38.38) 48 500 (37.84) 35 708 (27.94) 52 304 (40.09)
West 25 396 (19.04) 34 032 (26.55) 38 912 (30.44) 20 887 (16.01)
Median household income for the patient’s ZIP code
0 to 25th percentile 37 608 (28.97) 33 609 (26.86) 31 385 (25.17) 37 514 (29.50) 0.01
26th to 50th percentile 37 239 (28.69) 31 260 (24.98) 32 795 (26.30) 31 285 (24.60)
51st to 75th percentile 29 511 (22.73) 31 801 (25.41) 31 235 (25.05) 31 263 (24.59)
76th to 100th percentile 25 457 (19.61) 28 469 (22.75) 29 280 (23.48) 27 099 (21.31)
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1.58; 95% CI 1.45 to 1.73), 29% (OR 1.29; 95% CI 1.17 to
1.41), and 17% (OR 1.17; 95% CI 1.06 to 1.29), respectively
(Table 4).
After adjustment for Elixhauser comorbidities, hospital
location and teaching status, sex, race or ethnicity, and age, a
lower mean annual hospital case volume for the treatment of
CS was associated with signiﬁcantly increased odds of in-
hospital mortality. When comparing odds of mortality to
patients in quartile 4, adjusting demonstrated increases in the
odds of 27% (OR 1.27; 95% CI 1.15 to 1.40), 20% (OR 1.20;
95% CI 1.08 to 1.32), and 12% (OR 1.12; 95% CI 1.01 to 1.24),
respectively (Table 4). Although the odds of mortality remain
signiﬁcant, the unadjusted model yielded a wider range of ORs
than the adjusted model. In addition, a statistically signiﬁcant
decrease in incidence of overall adjusted mortality was seen
in comparison of hospital quartiles 1 through 4 (42.0%, 40.7%,
39.3%, and 37.0%, respectively) (Table 4).
Discussion
In this study, we demonstrated that an increase in hospital
volume of patients with CS was associated with improved in-
hospital mortality. We further demonstrated that lower
volume hospitals were less likely to offer aggressive and
speciﬁc treatments for CS, and that may partially explain
these differences in mortality. These ﬁndings remained robust
after multivariate adjustment for relevant confounders.
There are a number of potential reasons why hospitals
with high volumes of CS cases had lower mortality rates for
CS. A more central factor that may contribute to this inverse
relationship between hospital volume and outcome in CS is
signiﬁcant difference in the use of currently recommended
therapies between the hospital quartiles (Table 2). Of partic-
ular note are the signiﬁcant differences in the incidence of
deﬁnitive revascularization therapies (PCI and CABG) and
temporizing therapeutic measures (IABP, biventricular assist
devices, extracorporeal membrane oxygenation, and Tandem-
Heart devices). The primary therapy that has a demonstrated
mortality beneﬁt for patients with acute myocardial infarction
and CS is early revascularization. Previous work has demon-
strated a 13% increase in survival among patients who
received early revascularization.28 This survival beneﬁt con-
ferred by early revascularization was found to be independent
of revascularization technique (whether PCI or CABG) and was
consistent across age groups. Interestingly, despite control-
ling for early revascularization, center volume remained
independently associated with inpatient mortality. This may
be partially explained by the more frequent use of supportive
therapies for multiple organ dysfunction such as hemodialysis
in the higher volume centers. Of note, the highest volume
centers exhibited a lower rate of PCI and IABP use than the
centers in the second-highest volume quartile. The highest
volume centers, however, displayed higher rates of surgical
revascularization and valvular surgical intervention. This
raises a question of whether recognition of etiological factors
of CS, particularly with regard to valvular pathology, is
somewhat evident or, most likely, whether referral to the
highest volume centers is often for advanced therapies not
offered at small or medium-sized hospitals. We also report
signiﬁcant differences in commonly practiced but adjunctive
mechanical supportive therapies such as IABP or mechanical
circulatory support among quartiles 1 through 4. These
devices serve as a bridge lending support, viability, and time,
often after revascularization or supporting the CS patient
through to recovery.
Our study broadens the existing body of literature on
the relationship between hospital volume and outcome in
patients receiving cardiovascular care. Previous work has
Table 4. Association Between Hospital Volume and Risk-Adjusted Mortality
Annual Hospital Volume of Cardiogenic Shock
≤27 Cases 28 to 58 Cases 59 to 106 Cases ≥107 Cases
No. of hospitals, % 2046 (76.49) 366 (13.68) 177 (6.62) 86 (3.21)
Odds ratio, 95% CI
Unadjusted model 1.58 (1.45 to 1.73) 1.29 (1.17 to 1.41) 1.17 (1.06 to 1.29) 1.00 [Reference]
Multivariate model* 1.27 (1.15 to 1.40) 1.20 (1.08 to 1.32) 1.12 (1.01 to 1.24) 1.00 [Reference]
Mortality incidence, 95% CI
Unadjusted model 45.32 (44.53 to 46.11) 40.27 (39.25 to 41.29) 37.96 (36.66 to 39.28) 34.40 (32.53 to 36.32)
Multivariate model* 41.97 (40.87 to 43.08) 40.72 (39.52 to 41.93) 39.31 (37.91 to 40.72) 37.01 (35.11 to 38.96)
MI indicates myocardial infarction.
*Adjusted for age group, sex, race, acute MI, early revascularization, hemodialysis, teaching status of the hospital, hospital region, median household income for the patient’s ZIP code,
mechanical ventilation, valvular disease, pulmonary circulation disease, peripheral vascular disease, hypertension, paralysis, neurological disorders, chronic pulmonary disease, diabetes
with and without chronic complications, hypothyroidism, renal failure, liver disease, peptic ulcer disease, AIDS, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid
arthritis, coagulopathy, obesity, weight loss, ﬂuid and electrolyte disorders, chronic blood loss anemia, deﬁciency anemias, alcohol abuse, drug abuse, psychoses, depression.
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demonstrated a mortality beneﬁt in higher-volume centers in
the treatment of certain etiologies of CS including acute
myocardial infarction and heart failure.29,30 To our knowledge,
this study is the ﬁrst to deﬁne this relationship for the speciﬁc
diagnosis of CS.
Interestingly, in the multivariate analysis (Table 5), we
found certain risk factors (ie, anemia and obesity) known to
portend poor prognosis in coronary artery disease to have a
protective effective in CS. Chronic anemia, after multivariate
adjustment for confounding, was found to be associated
with decreased mortality. This result compares well with
Sherwood et al, who demonstrated increased mortality
associated with blood transfusions in anemic patients with
acute coronary syndrome.31 Obesity also conferred a
protective effect on multivariate adjustment. This effect with
obesity has been demonstrated previously in patients with
other critical illnesses including septic shock and heart
failure.32,33 The likely mechanism that confers this protec-
tion is a blunted inﬂammatory cytokine response in obese
patients.
Table 5. Multivariate Model
Variables Odds Ratio (95% CI)
Cardiogenic shock quartiles
>106 cases 1.00 [Reference]
59 to 106 cases 1.12 (1.01 to 1.24)
28 to 58 cases 1.20 (1.08 to 1.32)
<28 cases 1.27 (1.15 to 1.40)
Age group, y
<18 1.00 [Reference]
18 to 44 1.07 (0.99 to 1.16)
45 to 64 1.67 (1.55 to 1.81)
65 to 84 3.12 (2.86 to 3.40)
>85 4.14 (2.03 to 8.44)
Race
White 1.00 [Reference]
Black 0.97 (0.91 to 1.02)
Hispanic 1.02 (0.95 to 1.09)
Asian or Pacific Islander 1.01 (0.91 to 1.11)
Native American 1.08 (0.86 to 1.35)
Other 1.03 (0.94 to 1.12)
Female sex 1.05 (1.02 to 1.09)
Valvular disease 1.06 (1.00 to 1.13)
Acute MI 1.23 (1.18 to 1.28)
Pulmonary circulation disease 1.13 (1.03 to 1.24)
Peripheral vascular disease 1.29 (1.22 to 1.36)
Hypertension 1.04 (1.00 to 1.08)
Paralysis 0.96 (0.87 to 1.07)
Other neurological disorders 1.41 (1.32 to 1.50)
Chronic pulmonary disease 0.87 (0.83 to 0.90)
Diabetes without chronic complications 1.09 (1.05 to 1.14)
Diabetes with chronic complications 0.93 (0.86 to 1.00)
Hyperthyroidism 1.00 (0.94 to 1.07)
Renal failure 1.03 (0.98 to 1.07)
Liver disease 1.55 (1.41 to 1.72)
Peptic ulcer disease 0.71 (0.32 to 1.56)
AIDS 1.30 (0.90 to 1.89)
Lymphoma 1.44 (1.21 to 1.72)
Metastatic cancer 2.05 (1.81 to 2.31)
Solid tumor without metastasis 1.50 (1.33 to 1.69)
Rheumatoid arthritis 1.19 (1.06 to 1.35)
Coagulopathy 1.13 (1.06 to 1.20)
Obesity 0.87 (0.80 to 0.93)
Weight loss 0.59 (0.55 to 0.63)
Fluid and electrolyte disorders 1.19 (1.15 to 1.23)
Continued
Table 5. Continued
Variables Odds Ratio (95% CI)
Chronic blood loss anemia 0.63 (0.55 to 0.73)
Deficiency anemias 0.77 (0.73 to 0.81)
Alcohol abuse 0.88 (0.80 to 0.96)
Drug abuse 0.84 (0.75 to 0.95)
Psychoses 0.77 (0.68 to 0.87)
Depression 0.86 (0.78 to 0.94)
Teaching status
Rural 1.00 [Reference]
Urban nonteaching 0.94 (0.85 to 1.03)
Urban teaching 0.97 (0.88 to 1.08)
Hospital region
Northeast 1.00 [Reference]
Midwest 0.96 (0.88 to 1.05)
South 0.99 (0.92 to 1.06)
West 0.94 (0.86 to 1.02)
Median household income for patient’s ZIP code
0 to 25th percentile 1.00 [Reference]
26th to 50th percentile 0.97 (0.93 to 1.01)
51st to 75th percentile 0.97 (0.92 to 1.02)
76th to 100th percentile 0.95 (0.90 to 1.00)
Mechanical ventilation 2.75 (2.63 to 2.88)
Hemodialysis 1.33 (1.24 to 1.42)
No early revascularization 2.23 (2.14 to 2.33)
MI indicates myocardial infarction.
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Because the in-hospital mortality associated with CS is
almost 5% higher in the lowest quartile hospitals than the
highest quartile hospitals, early aggressive measures, includ-
ing transfer to a higher volume center, could be considered by
lower volume hospitals when managing this cohort of
severely ill patients. This approach would be consistent with
current American College of Cardiology recommendations for
triage and immediate transfer to a PCI-capable facility with
surgical backup for patients with acute coronary syndromes
because revascularization has demonstrated a mortality
beneﬁt at both 6 and 12 months when compared with
medical stabilization.28,34
Our study has certain limitations. Although billing diagno-
ses are captured by these types of administrative databases,
the lack of laboratory data does not permit the severity of
metabolic disarray to be quantiﬁed. Consequently, although
some conditions may be denoted, the signiﬁcance of those
conditions cannot be determined. Furthermore, despite the
wide scope and established validity of this database, coding
accuracy and consistency of data collected are dependent on
coding expertise and experience. Although the sensitivity of
the ICD-9 code for CS is only moderate, the large sample size
and high speciﬁcity make this cohort appropriate for this
study. In addition, the temporal relationship of interventions
and presence of pathology on admission, as opposed to
development during hospitalization, is difﬁcult to discern from
the database alone. Many cases of CS may evolve during the
hospital course, and etiology may be endogenous or iatro-
genic. Discrimination of these variables is unachievable within
the present methodology and would rely on previous
standards such as a retrospective chart review. Mortality of
patients within 24 hours of admission may reﬂect inherent
severity of disease on presentation rather than treatment
discrepancies between different volume hospitals. Because
data regarding timing of mortality are unavailable in this
administrative database, it is admittedly impossible to exclude
this potential confounder. Despite our mortality being similar
to a recently published randomized control trial involving
patients with CS, caution should be used when comparing trial
mortalities with observational data.9 We excluded patients
transferred to any acute-care facility because transfer to a
high-volume center may represent a competing outcome. We
acknowledge that this sound methodology does not allow
investigation of the types of patients who are transferred and
is an avenue worthy of further examination.
In conclusion, our study demonstrated an association
between mean annual CS volume and inpatient mortality with
more frequent use of both standard supportive and revascu-
larization techniques in the higher volume centers. Future
directions may include examining whether early stabilization
and transfer improve outcomes of patients with CS who are
admitted to lower volume centers.
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